Glioblastoma and other intracranial tumors elicit systemic sympathetic hyperactivity that limits immunotherapeutic responses
S. J. Lorrey, L. Wachsmuth, J. Finlay, C. Neff, K. Ayasoufi, J. Waibl Polania, A. Hoyt-Miggelbrink, M. Price, L. Rein, S. Dell, R. Reesman, X. Cui, A. Hawley, E. Lerner, D. Wilkinson, , P. E. Fecci
This study shows that intracranial tumors cause systemic sympathetic hyperactivity, impairing T cell function and limiting immunotherapy, and that beta-adrenergic blockade improves outcomes in mouse models and human patients.
bioRxiv · Nov 2, 2023 · PreprintImmunology